Henry Schein (NASDAQ:HSIC) Announces Quarterly Earnings Results

Henry Schein (NASDAQ:HSIC) announced its earnings results on Tuesday. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05, Briefing.com reports. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The company’s revenue was up .4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.32 earnings per share. Henry Schein updated its FY 2024 guidance to 4.740-4.820 EPS.

Henry Schein Stock Down 0.4 %

Shares of Henry Schein stock opened at $69.72 on Thursday. Henry Schein has a 52-week low of $62.12 and a 52-week high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55. The business’s 50 day simple moving average is $70.59 and its 200 day simple moving average is $69.78. The firm has a market cap of $8.83 billion, a PE ratio of 25.93, a P/E/G ratio of 2.08 and a beta of 0.87.

Insider Activity at Henry Schein

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at $4,978,026.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on HSIC shares. JPMorgan Chase & Co. lowered their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday. Barrington Research restated an “outperform” rating and set a $82.00 target price on shares of Henry Schein in a research report on Wednesday. UBS Group dropped their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Finally, Evercore ISI lifted their price objective on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $77.50.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.